Two of these agents, the mTOR inhibitor, everolimus, and α-specific PI3K inhibitor, alpelisib, are now established and licensed drugs for the treatment of advanced ER+ breast cancer when used in combination with ET [83–85]. The gene discussed is PIK3CA; the disease is breast carcinoma.